Summary
Clindamycin phosphate was given in a dose of 3.9 gr/24 hr (60 mg/kg/24 hr for children) to 20 patients aged from 6 to 84 years and suffering from a severe infection, due to Bacteroides fragilis in 10 cases. This antibiotic was given by continuous i.v. infusion without any serious side-effects. The average serum and urinary levels obtained were 11.3 and 650 gamma/ml respectively. In the majority of cases this indicates marked antibacterial activity, not only against gram-positive germs but also against B. fragilis. The overall therapeutic assessment can be summarized as follows: 12 recoveries (eight B. fragilis infections), three partial successes and four failures (one Cl. perfringens septicemia and one B. fragilis septicemia). The results are uninterpretable in the latter case.
Zusammenfassung
Klinische und mikrobiologische Untersuchungen. Clindamycin wurde in einer Dosis von 3,9 g/24 Stunden (60 mg/kg täglich im Kindesalter) 20 Patienten im Alter von 6–84 Jahren verabreicht, die unter schweren Infektionen litten, wovon 10 durch B. fragilis hervorgerufen wurden. Das Chemotherapeutikum wurde in Form einer Dauerinfusion ohne ernsthafte Nebenwirkungen angewendet. Die mittleren Serum- und Urinkonzentrationen lagen bei 11,3 bzw. 650µg/ml. In der Mehrheit der Fälle konnte eine hervorragende antibakterielle Aktivität festgestellt werden, und zwar gegenüber grampositiven Keimen wie auch gegenüber B. fragilis. Die Gesamtbewertung kann in folgender Weise zusammengefaßt werden: 12 Heilungen (8 davon bei B.-fragilis-Infektionen), 3 Teilerfolge und 4 Fehlschläge (1 davon war eine Cl.-perfringens-Sepsis und 1 eine B.-fragilis-Sepsis). In einem Fall war das Ergebnis nicht interpretierbar.
Similar content being viewed by others
References
Bartlett, J. C., Sutter, V. L., Finegold, S. M. Treatment of anaerobic infections with lincomycin and clindamycin. New Engl. J. Med. 287 (1972) 1006–1010.
Bennett, J. V., Brodie, J. L., Benner, E. J., Kirby, W. M. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl. Microbiol. 14 (1966) 170–177.
Chadwick, P. Bacteriological assessment of clindamycin, a new lincomycin derivative. Med. Microbiol. 4 (1971) 529–534.
Fass, R. J., Saslaw, S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am. J. Med. Sci. 263 (1972) 369–382.
Haldane, E. V., Van Rooyen, C. E. Treatment of severe Bacteroides infections with parenteral clindamycin. J. Can. Med. Assoc. 107 (1972) 1177–1181.
Kagnoff, M. F., Armstrong, D., Blevins, A. Bacteroides bacteremia. Experience in a hospital for neoplastic diseases. Cancer 29 (1972) 245–251.
Kislak, J. W. The susceptibility of Bacteroides fragilis to 24 antibiotics. J. Infect. Dis. 125 (1972) 295–299.
Manten, A.: In Side Effects of drugs. Volume VII, p. 388. Ed. Meyler, L. and Herxheimer, A.: Excerpta Medica Amsterdam.
Nastro, L. J., Finegold, S. M. Bactericidal activity of five antimicrobial agents against Bacteroides fragilis. J. Infect. Dis. 126 (1972) 104–107.
Okubadejo, O. A., Green, P. J., Payne, D. J. H. Bacteroides infection among hospital patients. Br. Med. J. 2 (1973) 212–214.
Schoutens, E., Labbe, M., Yourassowsky, E. Septicémies à B. fragilis. Incidence et sensibilité des souches aux antibiotiques. Path. Biol. 21 (1973) 349–353.
Steers, E., Foltz, E. L., Graves, B. S. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiot. Chemother. 9 (1959) 307–311.
Stiver, H. G., Ronald, A R.: Clinical and laboratory experience with clindamycin. Antimicr. Ag. Chemother. (1970) 481–485
Tracy, O., Gordon, A. M., Moran, F., Love, W. C., Mc Kenzie, P. Lincomycins in the treatment of Bacteroides Infections. Br. Med. J. 1 (1972) 280–282.
Wilson, W. R., Martin, W. J., Wilkowske, C. J., Washington, J. A. II Anaerobic bacteremia. Mayo Clin. Proc. 47 (1972) 639–646.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schoutens, E., Van Beers, D. & Yourassowsky, E. Clindamycin phosphate in severe infections mainly caused by bacteroides fragilis: Clinical and microbiological evaluation. Infection 2, 59–63 (1974). https://doi.org/10.1007/BF01642022
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01642022